DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
DiaMedica Therapeutics Stock Performance
Shares of NASDAQ:DMAC opened at $5.77 on Friday. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82. The firm has a fifty day moving average of $5.95 and a 200 day moving average of $5.05. The firm has a market capitalization of $246.73 million, a PE ratio of -10.30 and a beta of 1.52.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- How to trade using analyst ratings
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is the Euro STOXX 50 Index?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Utilities Stocks Explained – How and Why to Invest in Utilities
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
